2001年～2003年我院口服降糖药利用分析

目的 :评估我院口服降糖药的应用状况 ,为临床合理用药提供参考。方法 :采用限定日剂量分析方法 ,统计我院2001年～2003年口服降糖药的用药频度 (DDDs)、购药金额、每日药费等数据。结果 :口服降糖药的品种、数量及购药金额等逐年增长 ;DDDs排序前3位药品为二甲双胍、格列齐特、格列吡嗪 ;购药金额排序前3位药品为格列吡嗪、阿卡波糖、二甲双胍 ;购药金额序号与DDDs序号比值在0. 2～4之间。结论 :格列齐特和二甲双胍应用广泛 ,居主导地位 ,且价格较为合理 ;阿卡波糖价格昂贵 ,购药金额与DDDs的同步性较差。

Analysis on Use of Oral Hypoglycemic Drugs in Our Hospital from 2001 to 2003

OBJECTIVE: To evaluate the use of oral hypoglycemic drugs in our hospital in order to provide an reference for rational use of drugs in clinic. METHODS: DDDs, sales volume, and daily expenses of drugs in our hospital from 2001to 2003 were analyzed with the method of DDD analysis. RESULTS: The varieties, quantities and sales volumes of oral hypoglycemic drugs increased year by year. The top 3 hypoglycemic drugs in respect of DDDs were dimethylbigmide, gliclazide, and glipizide. The top 3 hypoglycemic drugs in respect of sales volume were glipizide, acarbose, and dimethylbimide. The ratio of sales volume sequencing to that of DDDs was between 0.2～4. CONCLUSIONS: Gliclazide and dimethylbimide are most widely used and their prices are reasonable; Acarbose is expensive, and its sales volume has not grown in pace with DDDs.